Synaptive Medical Inc., a leader in surgical planning and navigation
technology, announced today its intent to launch Evry™, a dedicated head
Magnetic Resonance Imaging (MRI) system intended to provide MRI directly
at the Point-of-Care (POC) at the QEII Health Sciences Centre (QEII) in
Halifax, Nova Scotia. The QEII will be one of the first adopters to use
the dedicated head-only MRI system as part of a four-year study in
partnership with the Nova
Scotia Halifax Authority (NSHA).
The purpose of Synaptive’s Evry, a dedicated head MRI, is specifically
for imaging patients in situations that require immediate decision
making, such as with acute stroke. The system comprises a
superconducting magnet, powerful gradients and a custom head coil
allowing it to be sited in areas previously inaccessible to MRI system
installation—for example, directly within emergency departments, ICUs
and other areas in the hospital where imaging of patients earlier in
their care cycle is critical to their outcomes.
“With the adoption of Evry, for the first time ever, MRI technology will
become accessible directly at a patient’s point of care within an
emergency department and other areas of the hospital, giving doctors
vital – and potentially life-saving – information when and where they
need it most,” said Peter Wehrly, CEO of Synaptive Medical. “Our team
spent years developing Evry and we are excited to partner with the Nova
Scotia Health Authority (NSHA) to study the impact it will have by
lowering the barrier to receiving an appropriate MRI.”
The QEII will be one of the first hospitals to use the machine on
patients, as part of a four-year study with the NSHA inside QEII’s Biomedical
Translational Imaging Centre (BIOTIC). The study aims to overcome
barriers that have previously prevented the routine use of MRI directly
in the emergency department and to help health care facilities make
informed decisions on the role that Evry will be able to provide at the
point of care.
“When someone has a stroke, a couple of minutes can mean the difference
between maintaining brain functions and losing them,” said Dr. Steven
Beyea, Scientific Director, BIOTIC at the NSHA. “By bringing MRI
directly to the point of care, Synaptive and the Nova Scotia Health
Authority will research the impact to patients, clinicians, and the
healthcare system more broadly, of providing physicians with faster and
more efficient access to MRI.”
Synaptive plans to pursue regulatory approval and adoption by leading
health care facilities around the world, with completion of installation
at QEII planned for fall 2019.
About Synaptive Medical
Synaptive Medical Inc., a Toronto-based medical device and technology
company, designs hardware and software that cross traditional barriers
in hospitals and improve patient care in and beyond the operating room.
Synaptive’s Modus V™ and integrated BrightMatter™ solutions—including
surgical planning, navigation and visualization, and an informatics
platform—give leading clinicians and healthcare systems the information
they need to ensure the best possible outcomes for patients.